Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH SEMA-2: Oral semaglutide vs DPP-4 inhibitors in type 2 diabetes
jRCT1011210032Completed
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Change in HbA1c at 24 weeks from baseline. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1011210032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011210032.